Analysts Anticipate Novartis AG (NYSE:NVS) to Announce $1.64 Earnings Per Share


Share on StockTwits

Brokerages expect Novartis AG (NYSE:NVS) to report earnings per share (EPS) of $1.64 for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Novartis’ earnings. Novartis reported earnings of $1.55 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 5.8%. The firm is expected to announce its next earnings results before the market opens on Tuesday, April 27th.

On average, analysts expect that Novartis will report full year earnings of $6.44 per share for the current financial year, with EPS estimates ranging from $6.35 to $6.55. For the next fiscal year, analysts forecast that the firm will report earnings of $6.88 per share, with EPS estimates ranging from $6.71 to $7.09. Zacks’ earnings per share calculations are an average based on a survey of analysts that follow Novartis.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Monday, January 25th. The company reported $1.34 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.37 by ($0.03). Novartis had a net margin of 14.71% and a return on equity of 24.39%. The firm had revenue of $12.77 billion during the quarter, compared to analyst estimates of $12.86 billion. During the same period in the previous year, the firm posted $1.32 earnings per share. The company’s quarterly revenue was up 3.0% compared to the same quarter last year.

NVS has been the subject of a number of recent research reports. Morgan Stanley reiterated an “overweight” rating on shares of Novartis in a report on Tuesday, February 2nd. Societe Generale reaffirmed a “buy” rating on shares of Novartis in a report on Tuesday, March 23rd. Deutsche Bank Aktiengesellschaft started coverage on Novartis in a report on Friday, January 15th. They set a “buy” rating for the company. Sanford C. Bernstein started coverage on Novartis in a report on Monday, March 22nd. They set a “market perform” rating for the company. Finally, Cowen downgraded Novartis from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $110.00 to $105.00 in a report on Monday, February 1st. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. Novartis presently has an average rating of “Hold” and an average price target of $108.50.

Several institutional investors have recently bought and sold shares of NVS. Phoenix Wealth Advisors purchased a new stake in shares of Novartis in the 4th quarter valued at about $27,000. Regent Peak Wealth Advisors LLC acquired a new position in Novartis in the 4th quarter valued at about $34,000. Addison Advisors LLC acquired a new position in Novartis in the 4th quarter valued at about $40,000. Veriti Management LLC acquired a new position in Novartis in the 4th quarter valued at about $42,000. Finally, Hoese & Co LLP acquired a new position in Novartis in the 4th quarter valued at about $42,000. 9.86% of the stock is owned by institutional investors and hedge funds.

NYSE:NVS opened at $86.30 on Thursday. The firm has a market cap of $197.51 billion, a PE ratio of 27.93, a price-to-earnings-growth ratio of 1.76 and a beta of 0.59. The stock has a fifty day moving average price of $86.31 and a 200 day moving average price of $88.58. Novartis has a 12-month low of $77.04 and a 12-month high of $98.52. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.49.

The company also recently announced an annual dividend, which was paid on Monday, March 15th. Stockholders of record on Friday, March 5th were issued a $3.3784 dividend. This is an increase from Novartis’s previous annual dividend of $3.04. This represents a dividend yield of 2.2%. The ex-dividend date was Thursday, March 4th. Novartis’s payout ratio is presently 39.69%.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products.

Read More: Hang Seng Index (HSI)

Get a free copy of the Zacks research report on Novartis (NVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.